Recent Updates
Recently added Catalysts
COYA Positive Sentiment

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Monday, October 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Coya Therapeutics has announced the completion of full enrollment in its Phase 2/3 ALSTARS Trial, which involves 120 participants. The trial is evaluating COYA 302, a combination of low-dose IL-2 and CTLA-4 Ig, aimed at treating amyotrophic lateral sclerosis (ALS). This development marks a significant step in the company's research efforts in neurodegenerative disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Coya Therapeutics has completed full enrollment in the ALSTARS Trial.
  • The trial involves 120 participants, indicating strong interest and support.
  • COYA 302 is a promising treatment for ALS, targeting T-cell function.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+10%
120-day peak, hindsight
Typical move
2%
average across 2 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
COYA 302
Phase 2 · Amyotrophic Lateral Sclerosis (ALS)

Full Press Release Details

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced full enrollment of the planned 120 participants in the Company’s Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the potential treatment of amyotrophic lateral scle

Frequently Asked Questions

What is the ALSTARS Trial?

The ALSTARS Trial is a Phase 2/3 clinical study evaluating COYA 302 for ALS treatment.

How many participants are in the ALSTARS Trial?

The trial has a total of 120 participants enrolled.

What does COYA 302 consist of?

COYA 302 is a combination of proprietary low-dose IL-2 and CTLA-4 Ig.

What condition is COYA 302 targeting?

COYA 302 is aimed at treating amyotrophic lateral sclerosis (ALS).

ShareAdd on Google
Tags: COYA Coya Therapeutics COYA 302 ALS Phase 2/3 trial neurodegenerative disorders
Last updated: Oct 5, 2026

Biotech snapshot

Cash runway
$43M liquidity · $2M/mo burn
~16 mo
Low dilution risk
Lead asset
COYA 302Phase 2
Amyotrophic Lateral Sclerosis (ALS) →

Catalyst track record

+10%
best trade around COYA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for COYA.

See every catalyst's timing & PoA →